Heart progress trumpeted by Labour
March 9, 2005The government has trumpeted its progress on tackling the UK's biggest killer, cardiovascular disease, and launched a new chapter of …
Potential blockbuster Tysabri pulled after patient death
March 9, 2005Sales and Marketing
Elan and Biogen Idec have stopped marketing Tysabri (natalizumab), their new multiple sclerosis treatment, and asked doctors not to prescribe …
ABPI to oppose strictest measures in pan-European code of practice
March 3, 2005Sales and Marketing
A pan-European code of practice is being drawn up by the pharmaceutical industry organisation EFPIA in response to continuing criticism …
GSK rebrands AIDS drugs to foil illegal imports
March 2, 2005Sales and Marketing
GlaxoSmithKline has rebranded its Aids drugs supplied to sub-Saharan Africa to stop illegal re-importation to Europe.The company said parallel importers …
Quicker service for cancer patients but ‘black spots’ persist
March 2, 2005Cancer patients are being seen more quickly but there is still room for improvement, says a National Audit Office report …
NICE acts to speed lung cancer diagnosis and treatment
March 2, 2005Patients showing symptoms of lung cancer should be offered an urgent referral to a chest physician, according to NICE recommendations …
Singulair gains dual asthma-hayfever indication
March 2, 2005Sales and Marketing
Merck Sharpe & Dohme's blockbuster oral asthma treatment Singulair has received an expanded UK licence for the treatment of adult …
NHS is behind us, says rep-free Takeda
March 1, 2005Sales and Marketing Davis, Takeda, sales and marketing
Takeda UK says new market research shows healthcare professionals and NHS managers are in favour of its revolutionary move away …
Cymbalta approved for second indication
February 24, 2005Sales and Marketing
Cymbalta has received European approval for diabetic peripheral neuropathic pain (DPNP) in adults, with its marketers keen to meet what …
Reassessing medical communications
February 24, 2005It's time to be less defensive about perfectly legitimate medical communications methods providing contentious 'sharp practices' can be consigned to …
Sankyo and Daiichi set to continue Japanese consolidation
February 24, 2005Sales and Marketing
Two of Japan's leading pharmaceutical companies Sankyo and Daiichi look set to merge later this year, accelerating consolidation in the …
FDA panel clears Vioxx return to market
February 21, 2005Sales and Marketing
An FDA panel has narrowly voted in favour of allowing Vioxx to return to the market, after concluding it carries …
IMS and Innovex announce UK alliance
February 17, 2005Sales and Marketing
Pharma data consultants IMS have announced a new alliance with contract sales provider Innovex to supply its field forces with …
ADHD latest drugs to be hit by safety warnings
February 17, 2005Sales and Marketing
Attention deficit hyperactivity disorder (ADHD) treatments are the latest class of drugs to be hit by safety warnings, with regulators …
New FDA drug safety board to be more independent
February 17, 2005Sales and Marketing
A new independent FDA board will be set up to monitor drug safety and issue warnings to doctors and patients …
Latest content
FibroFind appoints Lee Borthwick as CEO
